BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1097 related articles for article (PubMed ID: 25499080)

  • 1. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin's antitumor activity in vivo.
    Sun H; Zheng X; Wang Q; Yan J; Li D; Zhou Y; Lin Y; Zhang L; Wang X
    Anticancer Drugs; 2012 Nov; 23(10):1039-46. PubMed ID: 22760211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-κB activity is downregulated by KRAS knockdown in SW620 cells via the RAS-ERK-IκBα pathway.
    Lin G; Tang Z; Ye YB; Chen Q
    Oncol Rep; 2012 May; 27(5):1527-34. PubMed ID: 22327383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells.
    Wu CC; Yu CT; Chang GC; Lai JM; Hsu SL
    Biochem Biophys Res Commun; 2011 Feb; 405(2):168-72. PubMed ID: 21216229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer.
    Yang G; Xiao X; Rosen DG; Cheng X; Wu X; Chang B; Liu G; Xue F; Mercado-Uribe I; Chiao P; Du X; Liu J
    Clin Cancer Res; 2011 Apr; 17(8):2181-94. PubMed ID: 21339307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
    Zhang X; Qi Z; Yin H; Yang G
    Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
    Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
    Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 gene expression and 2-methoxyestradiol treatment differentially induce nuclear factor kappa B activation in human lung cancer cells with different p53 phenotypes.
    Rath PC; Mukhopadhyay T
    DNA Cell Biol; 2009 Dec; 28(12):615-23. PubMed ID: 19715480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells.
    Jiang XH; Wong BC; Lin MC; Zhu GH; Kung HF; Jiang SH; Yang D; Lam SK
    Oncogene; 2001 Nov; 20(55):8009-18. PubMed ID: 11753684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
    Dong QG; Sclabas GM; Fujioka S; Schmidt C; Peng B; Wu T; Tsao MS; Evans DB; Abbruzzese JL; McDonnell TJ; Chiao PJ
    Oncogene; 2002 Sep; 21(42):6510-9. PubMed ID: 12226754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexabromocyclododecane and polychlorinated biphenyls increase resistance of hepatocellular carcinoma cells to cisplatin through the phosphatidylinositol 3-kinase/protein kinase B pathway.
    An J; Wang X; Guo P; Zhong Y; Zhang X; Yu Z
    Toxicol Lett; 2014 Aug; 229(1):265-72. PubMed ID: 24960055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer.
    Guo J; Feng Z; Huang Z; Wang H; Lu W
    Mol Cells; 2014 Sep; 37(9):664-71. PubMed ID: 25234467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
    Shishodia S; Gutierrez AM; Lotan R; Aggarwal BB
    Cancer Res; 2005 Oct; 65(20):9555-65. PubMed ID: 16230421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis of human fibrosarcoma HT-1080 cells by epigallocatechin-3-O-gallate via induction of p53 and caspases as well as suppression of Bcl-2 and phosphorylated nuclear factor-κB.
    Lee MH; Han DW; Hyon SH; Park JC
    Apoptosis; 2011 Jan; 16(1):75-85. PubMed ID: 20963498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
    Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y
    Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.